NVAX - NOVAVAX INC
IEX Last Trade
8.49
-4.390 -51.708%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:58 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$12.88
-4.39
-34.08%
Fundamental analysis
31%
Profitability
36%
Dept financing
25%
Liquidity
21%
Performance
30%
Performance
5 Days
-2.18%
1 Month
-8.69%
3 Months
-29.32%
6 Months
-39.21%
1 Year
68.18%
2 Year
-3.95%
Key data
Stock price
$8.49
DAY RANGE
$8.60 - $12.88
52 WEEK RANGE
$3.80 - $23.86
52 WEEK CHANGE
$72.27
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Stanley C. Erck
Region: US
Website: novavax.com
Employees: 1,990
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: novavax.com
Employees: 1,990
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Recent news